Literature DB >> 16755843

MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles.

Tillmann Cyrus1, Dana R Abendschein, Shelton D Caruthers, Thomas D Harris, Veronica Glattauer, Jerome A Werkmeister, John A M Ramshaw, Samuel A Wickline, Gregory M Lanza.   

Abstract

In this study, porcine carotid arteries were subjected to balloon overstretch injury followed by local delivery of paramagnetic nanoparticles targeted to alphavbeta3-integrin expressed by smooth muscle cells or collagen III within the extracellular matrix. Carotid T1-weighted angiography and vascular imaging was performed at 1.5T. While MR angiograms were indistinguishable between control and targeted vessel segments, alphavbeta3-integrin-and collagen Ill-targeted nanoparticles spatially delineated patterns and volumes of stretch injury. In conclusion, MR molecular imaging with alphavbeta3-integrin or collagen Ill-targeted nanoparticles enables the non-invasive, three-dimensional characterization of arterial pathology unanticipated from routine angiography.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16755843     DOI: 10.1080/10976640600580296

Source DB:  PubMed          Journal:  J Cardiovasc Magn Reson        ISSN: 1097-6647            Impact factor:   5.364


  12 in total

Review 1.  Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.

Authors:  Biana Godin; Jason H Sakamoto; Rita E Serda; Alessandro Grattoni; Ali Bouamrani; Mauro Ferrari
Journal:  Trends Pharmacol Sci       Date:  2010-02-19       Impact factor: 14.819

Review 2.  Enabling individualized therapy through nanotechnology.

Authors:  Jason H Sakamoto; Anne L van de Ven; Biana Godin; Elvin Blanco; Rita E Serda; Alessandro Grattoni; Arturas Ziemys; Ali Bouamrani; Tony Hu; Shivakumar I Ranganathan; Enrica De Rosa; Jonathan O Martinez; Christine A Smid; Rachel M Buchanan; Sei-Young Lee; Srimeenakshi Srinivasan; Matthew Landry; Anne Meyn; Ennio Tasciotti; Xuewu Liu; Paolo Decuzzi; Mauro Ferrari
Journal:  Pharmacol Res       Date:  2010-01-05       Impact factor: 7.658

Review 3.  Gd-based macromolecules and nanoparticles as magnetic resonance contrast agents for molecular imaging.

Authors:  Ching-Hui Huang; Andrew Tsourkas
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 4.  Imaging atherosclerosis and vulnerable plaque.

Authors:  Mehran M Sadeghi; David K Glover; Gregory M Lanza; Zahi A Fayad; Lynne L Johnson
Journal:  J Nucl Med       Date:  2010-04-15       Impact factor: 10.057

Review 5.  Nanotechnology in interventional cardiology.

Authors:  Tillmann Cyrus; Samuel A Wickline; Gregory M Lanza
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011-07-11

6.  Fluorine (19F) MRS and MRI in biomedicine.

Authors:  Jesús Ruiz-Cabello; Brad P Barnett; Paul A Bottomley; Jeff W M Bulte
Journal:  NMR Biomed       Date:  2010-09-15       Impact factor: 4.044

Review 7.  Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents.

Authors:  Rohun U Palekar; Andrew P Jallouk; Gregory M Lanza; Hua Pan; Samuel A Wickline
Journal:  Nanomedicine (Lond)       Date:  2015       Impact factor: 5.307

Review 8.  Nanotechnology in medical imaging: probe design and applications.

Authors:  David P Cormode; Torjus Skajaa; Zahi A Fayad; Willem J M Mulder
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-12-04       Impact factor: 8.311

9.  Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury.

Authors:  Tillmann Cyrus; Huiying Zhang; John S Allen; Todd A Williams; Grace Hu; Shelton D Caruthers; Samuel A Wickline; Gregory M Lanza
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-21       Impact factor: 8.311

Review 10.  Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine.

Authors:  Xue-Qing Zhang; Xiaoyang Xu; Nicolas Bertrand; Eric Pridgen; Archana Swami; Omid C Farokhzad
Journal:  Adv Drug Deliv Rev       Date:  2012-08-17       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.